- Home
- BSTZ vs RCUS Comparison
BSTZ vs RCUS Comparison
Compare BSTZ & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSTZ
- RCUS
- Stock Information
- Founded
- BSTZ 2019
- RCUS 2015
- Country
- BSTZ United States
- RCUS United States
- Employees
- BSTZ N/A
- RCUS N/A
- Industry
- BSTZ Trusts Except Educational Religious and Charitable
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- BSTZ Finance
- RCUS Health Care
- Exchange
- BSTZ Nasdaq
- RCUS Nasdaq
- Market Cap
- BSTZ 1.5B
- RCUS 1.2B
- IPO Year
- BSTZ N/A
- RCUS 2018
- Fundamental
- Price
- BSTZ $23.03
- RCUS $19.54
- Analyst Decision
- BSTZ
- RCUS Buy
- Analyst Count
- BSTZ 0
- RCUS 8
- Target Price
- BSTZ N/A
- RCUS $27.63
- AVG Volume (30 Days)
- BSTZ 303.2K
- RCUS 1.4M
- Earning Date
- BSTZ 01-01-0001
- RCUS 10-28-2025
- Dividend Yield
- BSTZ 8.31%
- RCUS N/A
- EPS Growth
- BSTZ N/A
- RCUS N/A
- EPS
- BSTZ 0.71
- RCUS N/A
- Revenue
- BSTZ N/A
- RCUS $240,000,000.00
- Revenue This Year
- BSTZ N/A
- RCUS N/A
- Revenue Next Year
- BSTZ N/A
- RCUS N/A
- P/E Ratio
- BSTZ $26.69
- RCUS N/A
- Revenue Growth
- BSTZ N/A
- RCUS N/A
- 52 Week Low
- BSTZ $14.11
- RCUS $6.50
- 52 Week High
- BSTZ $19.43
- RCUS $22.11
- Technical
- Relative Strength Index (RSI)
- BSTZ 64.95
- RCUS 65.07
- Support Level
- BSTZ $21.02
- RCUS $16.41
- Resistance Level
- BSTZ $23.12
- RCUS $22.11
- Average True Range (ATR)
- BSTZ 0.35
- RCUS 1.26
- MACD
- BSTZ 0.12
- RCUS 0.16
- Stochastic Oscillator
- BSTZ 99.51
- RCUS 54.34
About BSTZ BlackRock Science and Technology Term Trust of Beneficial Interest
BlackRock Science and Technology Trust II is a non-diversified, closed-end management investment company. The trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. Its portfolio consists of Equity Securities, Options, Preferred Securities, Convertible Securities, Depositary Receipts, Non-U.S. Securities, Emerging Markets Investments, Restricted and Illiquid Investments, Private Company Investments, Corporate Bonds, and other investments. The trust seeks to Invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range from the development, advancement, and use of science and/or technology.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.